SCHEMBL711140

SCHEMBL711140

CN(C)c1ccc(CNCc2csc(Nc3ccc(S(=O)(=O)Nc4nccs4)cc3)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.55
NAMPT P43490 1/20 0.46
SCN3A Q9NY46 4/20 0.46
TDP1 Q9NUW8 2/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
PKM P14618 3/20 0.45
ALDH1A1 P00352 2/20 0.44
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
EGFR P00533 1/20 0.43
KDR P35968 1/20 0.43
SCN1A P35498 1/20 0.43
SCN1B Q07699 1/20 0.43
SCN5A Q14524 1/20 0.43
SCN8A Q9UQD0 1/20 0.43
LMNA P02545 2/20 0.43
PPIA P62937 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714319 0.88 LMNA (0.58) NAMPTSCN3ATDP1MEN1KMT2A
SCHEMBL713191 0.86 SCN3A (0.65) NAMPTSCN3ATDP1MEN1KMT2A
SCHEMBL710421 0.86 MEN1 (0.47) NAMPTSCN3ATDP1MEN1KMT2A
SCHEMBL711048 0.79 KMT2A (0.56) MEN1KMT2APKMALDH1A1EGFR
SCHEMBL712098 0.78 PKM (0.52) TDP1MEN1KMT2APKMALDH1A1
SCHEMBL713846 0.78 SCN1A (0.56) SCN3ATDP1MEN1KMT2APKM
SCHEMBL714055 0.78 PKM (0.54) NAMPTSCN3AMEN1KMT2APKM
SCHEMBL712663 0.78 LMNA (0.62) SCN3ATDP1MEN1KMT2AALDH1A1
SCHEMBL711873 0.77 ALOX12 (0.58) TDP1MEN1KMT2APKMALDH1A1
SCHEMBL711980 0.77 SCN1A (0.54) NAMPTSCN3ATDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A RXFP1 4010/4885NAMPT 687/4885SCN3A 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.